Winter JL, Stackhouse BL, Russell GB, Kute TE. Measurement of PTEN expression using tissue microarrays to determine a race-specific prognostic marker in breast cancer. Arch Pathol Lab Med. 2007 May;131(5):767-72.
Morrow CS, Peklak-Scott C, Bishwokarma B, Kute TE, Smitherman PK, Townsend AJ. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol 2006 Apr;69(4):1499-505.
O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS. 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta. 2005 Oct 1;1736(3):228-36.
Turner J, Koumenis C, Kute TE, Planalp RP, Brechbiel MW, Beardsley D, Cody B, Brown KD, Torti FM, Torti SV. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood. 2005 Nov 1;106(9):3191-9.
O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS. 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta. 2005 Oct 1;1736(3):228-36.
Shen YJ, Delong CJ, Terce F, Kute T, Willingham MC, Pettenati MJ, Cui Z. Polyploid Formation via Chromosome Duplication Induced by CTP:Phosphocholine Cytidylyltransferase Deficiency and Bcl-2 Overexpression: Identification of Two Novel Endogenous Factors. J Histochem Cytochem. 2005 Jun;53(6):725-33.
Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, Stackhouse C, Wilkins L, Evans I, Berry P, Rimmer K, Tucker E. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry. 2004 May;59B(1):24-31.
Xu M, Floyd HS, Greth SM, Chang WC, Lohman K, Stoyanova R, Kucera GL, Kute TE, Willingham MC, Miller MS. Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects. Toxicol Appl Pharmacol. 2004 Mar 1;195(2):232-46.
Kute TE, Lack CM, Willingham MW, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance in breast cancer cells. Cytometry. 2004 Jan; 57A(2): 86-93. [E-pub ahead of print]
Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan; 308(1): 260-7.
Wheeler YY, Kute TE, Willingham MC, Chen SY, Sane DC. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J. 2003 Sep;17(12):1733-5.
Molnar I, Kute T, Willingham MC, Powell BL, Dodge WH, Schwartz GG. 19-nor-1 alpha,25-dihydroxyvitamin D2 (particalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines. J Cancer Res Clin Oncol 2003;129(1):35-42.
Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr. 2002 Oct;132(10):3191-4.
Mayfield S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat. 2001 Nov;70(2):123-9.
Fang D, Hallman J, Sangha N, Kute TE, Hammarback JA, White WL, Setaluri V. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol. 2001 Jun;158(6):2107-15.
Trimboli AJ, Waite BM, Atsumi G, Fonteh AN, Namen AM, Clay CE, Kute TE, High KP, Willingham MC, Chilton FH. Influence of coenzyme A-independent transacylase and cyclooxygenase inhibitors on the proliferation of breast cancer cells. Cancer Res. 1999 Dec 15;59(24):6171-7.
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999 Oct;20(10):1905-11.
Russell RL, Pedersen AN, Kantor J, Geisinger K, Long R, Zbieranski N, Townsend A, Shelton B, Brunner N, Kute TE. Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer. 1998 Sep;78(6):710-7.
Parthasarathy N, Gotow LF, Bottoms JD, Kute TE, Wagner WD, Mulloy B. Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin. J Biol Chem. 1998 Aug 14;273(33):21111-4.
Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat. 1998 Jan;47(1):9-16.
Loeser RF, Varnum BC, Carlson CS, Goldring MB, Liu ET, Sadiev S, Kute TE, Wallin R. Human chondrocyte expression of growth-arrest-specific gene 6 and the tyrosine kinase receptor axl: potential role in autocrine signaling in cartilage. Arthritis Rheum. 1997 Aug;40(8):1455-65.
Kimball RE, Schlaerth JB, Kute TE, Schlaerth AC, Santoso J, Ballon SC, Spirtos NM. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance. Am J Obstet Gynecol. 1997 Jun;176(6):1319-26; discussion 1326-7.